The company focuses on developing Ciz1-targeted therapeutic products and related diagnostics for the early detection and management of lung cancer. They have successfully generated lead molecules specific to lung cancer and candidate diagnostics. Cizzle Biotech is particularly interested in the potential of the CIZ1 gene as a diagnostic biomarker for lung cancer.